HK1211938A1 - 新的吡啶衍生物 - Google Patents

新的吡啶衍生物

Info

Publication number
HK1211938A1
HK1211938A1 HK15112855.2A HK15112855A HK1211938A1 HK 1211938 A1 HK1211938 A1 HK 1211938A1 HK 15112855 A HK15112855 A HK 15112855A HK 1211938 A1 HK1211938 A1 HK 1211938A1
Authority
HK
Hong Kong
Prior art keywords
pyridine derivatives
novel pyridine
novel
derivatives
pyridine
Prior art date
Application number
HK15112855.2A
Other languages
English (en)
Inventor
奧利維耶‧加韋勒尤偉‧格雷瑟金原篤馬蒂亞斯‧內特科文斯蒂芬‧勒韋爾馬克‧羅杰斯-埃文斯迪迪埃‧羅姆巴赫坦賈‧舒爾茲-加施
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1211938A1 publication Critical patent/HK1211938A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
HK15112855.2A 2013-03-26 2015-12-30 新的吡啶衍生物 HK1211938A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26
PCT/EP2014/055797 WO2014154612A1 (en) 2013-03-26 2014-03-24 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
HK1211938A1 true HK1211938A1 (zh) 2016-06-03

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112855.2A HK1211938A1 (zh) 2013-03-26 2015-12-30 新的吡啶衍生物

Country Status (34)

Country Link
US (2) US10308659B2 (zh)
EP (1) EP2978755B1 (zh)
JP (1) JP6500010B2 (zh)
KR (1) KR20150135458A (zh)
CN (1) CN105121436B (zh)
AR (1) AR095721A1 (zh)
AU (1) AU2014243190B2 (zh)
BR (1) BR112015024272A2 (zh)
CA (1) CA2899168A1 (zh)
CL (1) CL2015002835A1 (zh)
CR (1) CR20150440A (zh)
DK (1) DK2978755T3 (zh)
EA (1) EA027569B1 (zh)
ES (1) ES2661737T3 (zh)
HK (1) HK1211938A1 (zh)
HR (1) HRP20180371T1 (zh)
HU (1) HUE036934T2 (zh)
IL (1) IL240496B (zh)
LT (1) LT2978755T (zh)
MA (1) MA38404B1 (zh)
MX (1) MX365921B (zh)
MY (1) MY174000A (zh)
NO (1) NO2978755T3 (zh)
PE (1) PE20151559A1 (zh)
PH (1) PH12015501933A1 (zh)
PL (1) PL2978755T3 (zh)
PT (1) PT2978755T (zh)
RS (1) RS56927B1 (zh)
SG (1) SG11201507994QA (zh)
SI (1) SI2978755T1 (zh)
TW (1) TWI628174B (zh)
UA (1) UA116239C2 (zh)
WO (1) WO2014154612A1 (zh)
ZA (1) ZA201505251B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3159339B1 (en) * 2014-06-09 2020-11-25 Sumitomo Chemical Company, Limited Method for producing pyridine compound
MX2018006802A (es) * 2015-12-09 2018-09-05 Hoffmann La Roche Derivados de fenilo como agonistas del receptor de canabinoides 2.
ES2847239T3 (es) * 2016-07-07 2021-08-02 Dow Agrosciences Llc Procedimientos para la preparación de 4-alcoxi-3-(acil o alquil)oxipicolinamidas
TW202334101A (zh) * 2017-04-06 2023-09-01 美商富曼西公司 殺真菌之噁二唑
CN110753690B (zh) * 2017-06-20 2023-12-05 豪夫迈·罗氏有限公司 吡啶衍生物
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
PE20210368A1 (es) 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
JP7454512B2 (ja) 2018-06-27 2024-03-22 エフ． ホフマン－ラ ロシュ アーゲー 優先的カンナビノイド２アゴニストとしてのピリジン及びピラジン誘導体
JP7456948B2 (ja) 2018-06-27 2024-03-27 エフ． ホフマン－ラ ロシュ アーゲー 放射性標識カンナビノイド受容体２リガンド
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
CN118302414A (zh) * 2021-10-22 2024-07-05 卡莫特医疗有限公司 用于抑制usp28的噁唑、噁二唑和吲哚衍生物
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082191A2 (en) * 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
AU2007281747B2 (en) 2006-08-07 2013-11-07 Ironwood Pharmaceuticals, Inc. Indole compounds
EP2211619A1 (en) * 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
MX2014015491A (es) 2012-07-04 2015-03-06 Hoffmann La Roche Nuevos derivados de adamantilo como agonistas del receptor 2 del canabinoide.
LT2928868T (lt) 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
UA114657C2 (uk) 2012-12-07 2017-07-10 Ф. Хоффманн-Ля Рош Аг Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
JP6322646B2 (ja) 2012-12-07 2018-05-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２受容体アゴニストとしての新規ピラジン誘導体
KR20150092282A (ko) 2012-12-07 2015-08-12 에프. 호프만-라 로슈 아게 신규한 피리딘 유도체
MY176797A (en) 2013-03-07 2020-08-21 Hoffmann La Roche Novel pyrazol derivatives
PE20161407A1 (es) 2014-04-04 2016-12-28 Hoffmann La Roche Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
JP6654574B2 (ja) 2014-04-04 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２アゴニストとして有用なピリジン−２−アミド

Also Published As

Publication number Publication date
UA116239C2 (uk) 2018-02-26
HRP20180371T1 (hr) 2018-04-06
MA38404B1 (fr) 2017-09-29
CN105121436A (zh) 2015-12-02
CA2899168A1 (en) 2014-10-02
HUE036934T2 (hu) 2018-08-28
PL2978755T3 (pl) 2018-05-30
EP2978755B1 (en) 2018-01-03
US20190248803A1 (en) 2019-08-15
TW201518287A (zh) 2015-05-16
CN105121436B (zh) 2018-07-27
KR20150135458A (ko) 2015-12-02
TWI628174B (zh) 2018-07-01
CL2015002835A1 (es) 2016-05-20
EA027569B1 (ru) 2017-08-31
MY174000A (en) 2020-03-03
SI2978755T1 (en) 2018-03-30
MA38404A1 (fr) 2017-01-31
AU2014243190A1 (en) 2015-07-30
US20160016968A1 (en) 2016-01-21
SG11201507994QA (en) 2015-10-29
PH12015501933B1 (en) 2016-01-11
WO2014154612A1 (en) 2014-10-02
DK2978755T3 (en) 2018-03-05
CR20150440A (es) 2015-10-08
AR095721A1 (es) 2015-11-04
JP2016516737A (ja) 2016-06-09
ES2661737T3 (es) 2018-04-03
PH12015501933A1 (en) 2016-01-11
ZA201505251B (en) 2016-07-27
PE20151559A1 (es) 2015-11-05
IL240496B (en) 2019-03-31
EA201591567A1 (ru) 2016-01-29
MX2015013629A (es) 2016-02-18
AU2014243190B2 (en) 2018-07-19
NO2978755T3 (zh) 2018-06-02
RS56927B1 (sr) 2018-05-31
JP6500010B2 (ja) 2019-04-10
BR112015024272A2 (pt) 2017-07-18
US10308659B2 (en) 2019-06-04
IL240496A0 (en) 2015-09-24
PT2978755T (pt) 2018-02-26
LT2978755T (lt) 2018-03-12
MX365921B (es) 2019-06-20
EP2978755A1 (en) 2016-02-03

Similar Documents

Publication Publication Date Title
HK1215795A1 (zh) 鵝膏毒素衍生物
HRP20170919T1 (hr) Novi derivati pirazola
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1211938A1 (zh) 新的吡啶衍生物
ZA201507657B (en) Pyridin-4-yl derivatives
ZA201601333B (en) Oxoquinazolinyl-butanamide derivatives
SG11201605189YA (en) Imidazopyrazinone derivatives
HK1213566A1 (zh) 新的四唑酮衍生物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230328